ARCUTIS BIOTHERAPEUTIC

Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

19 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 сен 2024 15:00:00 Источник Nasdaq GlobeNewswire

Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255

05 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

28 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire

Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

22 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire

CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

14 авг 2024 20:00:03 Источник Nasdaq GlobeNewswire

Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

14 авг 2024 15:00:00 Источник Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 авг 2024 15:00:00 Источник Nasdaq GlobeNewswire

Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024

01 авг 2024 15:00:00 Источник Nasdaq GlobeNewswire

Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.

29 июл 2024 06:35:00 Источник Nasdaq GlobeNewswire

Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

29 июл 2024 06:30:00 Источник Nasdaq GlobeNewswire

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

23 июл 2024 07:00:01 Источник Nasdaq GlobeNewswire

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

22 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

09 июл 2024 15:53:01 Источник Nasdaq GlobeNewswire

Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis

09 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 июл 2024 15:00:00 Источник Nasdaq GlobeNewswire

Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

10 июн 2024 13:30:00 Источник Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 июн 2024 15:00:00 Источник Nasdaq GlobeNewswire

Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

03 июн 2024 07:00:00 Источник Nasdaq GlobeNewswire

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update

14 май 2024 15:00:00 Источник Nasdaq GlobeNewswire